Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.  [electronic resource] 

 -  JAMA  Jan 1995 
 - 199-208 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0098-7484 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Cholesterol, HDL--blood<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Endometrial Hyperplasia--chemically induced<br/>Estrogen Replacement Therapy<br/>Estrogens, Conjugated (USP)--administration & dosage<br/>Female<br/>Fibrinogen--drug effects<br/>Glucose--metabolism<br/>Heart Diseases--epidemiology<br/>Humans<br/>Insulin--blood<br/>Medroxyprogesterone Acetate--administration & dosage<br/>Middle Aged<br/>Postmenopause--drug effects<br/>Risk Factors<br/>Systole--drug effects<br/>Weight Gain